Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Halozyme Therapeutics Inc Market Cap
The Halozyme Therapeutics Inc (HALO) share price is expected to increase by 4.02% over the next year. This is based on calculating the average 12-month share price estimate provided by 10 stock analysts who have covered HALO. Price targets range from $48 at the low end to $75 at the high end. The current analyst consensus for HALO is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 10 Wall Street analysts have assigned HALO 7 buy ratings, 2 hold ratings, and 1 sell ratings. This means that analysts expect Halozyme Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HALO. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of HALO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jessica Fye JP Morgan | Neutral | $57 | Downgrade | Sep 19, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $65 | Reiterates | Sep 16, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $65 | Reiterates | Sep 13, 2024 |
| Robert Wasserman Benchmark | Buy | $60 | Reiterates | Aug 8, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $65 | Reiterates | Aug 8, 2024 |
| Vikram Purohit Morgan Stanley | Overweight | $64 | Maintains | Aug 7, 2024 |
| Brendan Smith TD Cowen | Buy | $65 | Maintains | Aug 7, 2024 |
| Jessica Fye JP Morgan | Overweight | $52 | Maintains | Aug 6, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $65 | Reiterates | Aug 1, 2024 |
| Graig Suvannavejh Goldman Sachs | Neutral | $49 | Maintains | Jul 22, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $65 | Reiterates | Jul 16, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $65 | Reiterates | Jun 26, 2024 |
| Robert Wasserman Benchmark | Buy | $60 | Maintains | Jun 25, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $65 | Reiterates | Jun 24, 2024 |
| Joseph Catanzaro Piper Sandler | Neutral | $51 | Downgrade | Jun 7, 2024 |
| Mohit Bansal Wells Fargo | Overweight | $58 | Maintains | Jun 7, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $65 | Maintains | Jun 7, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $50 | Reiterates | Jun 4, 2024 |
| Mitchell Kapoor HC Wainwright & Co. | Buy | $50 | Reiterates | May 22, 2024 |
| Jason Butler JMP Securities | Market Outperform | $71 | Maintains | May 8, 2024 |
When did it IPO
2004
Staff Count
373
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Market Cap
$7.73B
In 2023, HALO generated $829.3M in revenue, which was a increase of 25.62% from the previous year. This can be seen as a signal that HALO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 20 Sep 2024
Sentiment - NEUTRAL
Source - Investors Business Daily
Summary - The top five biotech stocks currently share strong ratings, indicating positive investor sentiment and potential growth in the sector.
Why It Matters - Strong ratings for top biotech stocks indicate investor confidence, suggesting potential for growth and stability in the sector, influencing investment decisions.
Tue, 17 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Kaskela Law LLC is investigating Halozyme Therapeutics (NASDAQ: HALO) for potential securities law violations and breaches of fiduciary duty by its officers and directors.
Why It Matters - The investigation into Halozyme may indicate potential legal issues, affecting stock performance and shareholder confidence, which could lead to volatility in the company's share price.
Fri, 13 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Halozyme Therapeutics announced FDA approval for OCREVUS ZUNOVO™, a subcutaneous treatment for multiple sclerosis, expanding access for centers without IV infrastructure.
Why It Matters - The FDA approval of OCREVUS ZUNOVO™ enhances Halozyme's market position, potentially increasing revenue from broader patient access and simplifying treatment logistics, positively impacting stock performance.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Halozyme Therapeutics announced FDA approval for Roche's Tecentriq Hybreza™, the first subcutaneous anti-PD-(L)1 cancer immunotherapy, utilizing Halozyme's ENHANZE® technology.
Why It Matters - FDA approval of Tecentriq Hybreza™ enhances Halozyme's market position and revenue potential, signaling growth opportunities in the cancer treatment sector for investors.
Thu, 05 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Halozyme Therapeutics (HALO) reported earnings 30 days ago. Investors should monitor upcoming developments and market reactions for future stock performance insights.
Why It Matters - Earnings reports provide insights into a company's performance and future prospects, influencing stock valuation and investor sentiment, crucial for trading decisions.
Mon, 02 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Style Scores help investors identify top-rated stocks tailored to their investing style, providing a useful tool for stock selection.
Why It Matters - Zacks Style Scores help identify high-potential stocks aligned with specific investing strategies, aiding informed investment decisions and potentially enhancing portfolio performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
